Physician profile
Yon Park
NPI 1689601239
$1,807.21
in general payments reported to CMS, 2019-2025
27 companies · $488 in 2025
The $488 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.88 · 2020: $22.74 · 2021: $25.26 · 2022: $231 · 2023: $491 · 2024: $461 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,439.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $370.94 | 2022-2025 | Trodelvy |
| Celgene Corporation | $189.64 | 2023-2024 | Reblozyl, Pomalyst |
| Pharmacyclics LLC, An Abbvie Company | $133.69 | 2023 | Imbruvica |
| Abbvie INC. | $100.67 | 2024-2025 | |
| Janssen Biotech, INC. | $97.88 | 2020-2023 | Talvey, Tecvayli |
| Sirtex Medical INC | $95.84 | 2019-2022 | |
| Glaxosmithkline, LLC. | $89.02 | 2025 | Ojjaara, Jemperli, Zejula |
| Array Biopharma INC | $87.99 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Daiichi Sankyo INC. | $79.58 | 2023-2024 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $77.47 | 2022-2025 | Opdivo, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $67.62 | 2024 | Fruzaqla |
| Novartis Pharmaceuticals Corporation | $50.35 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $48.99 | 2025 | Libtayo |
| Taiho Oncology, INC. | $46.25 | 2022-2024 | |
| Dendreon Pharmaceuticals LLC | $36.01 | 2023 | Provenge |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $33.11 | 2022-2023 | Padcev |
| Astrazeneca Pharmaceuticals Lp | $32.76 | 2022 | |
| Pharmaessentia USA Corporation | $23.33 | 2023 | Besremi |
| Amgen INC. | $22.52 | 2022 | |
| Apellis Pharmaceuticals, INC. | $21.65 | 2023 | Empaveli |
| Csl Behring | $20.29 | 2022 | |
| Sobi, INC | $17.28 | 2023 | |
| Karyopharm Therapeutics INC. | $16.45 | 2022 | |
| Medtronic, INC. | $14.05 | 2021 | |
| Supernus Pharmaceuticals, INC. | $12.86 | 2023 | Qelbree |
| Eisai INC. | $11.21 | 2021 | |
| Secura Bio, INC. | $9.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yon Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.